# RENACTIF: Reduction of the Thrombotic Phenotype in Renal Insufficiency With N-AcetylCysteine

> **NCT03636932** · PHASE2 · COMPLETED · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 40 (actual)

## Conditions studied

- Chronic Kidney Diseases

## Interventions

- **DRUG:** N-acetylcysteine (NAC)
- **DRUG:** Placebo
- **BIOLOGICAL:** Blood sample
- **BIOLOGICAL:** Blood sample

## Key facts

- **NCT ID:** NCT03636932
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-30
- **Primary completion:** 2021-02-04
- **Final completion:** 2023-05-23
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03636932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03636932, "RENACTIF: Reduction of the Thrombotic Phenotype in Renal Insufficiency With N-AcetylCysteine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03636932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*